

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Cancelled)

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Currently Amended) A pharmaceutical composition which comprises an acceptable vehicle and at least two peptides which are peptide fraction obtained by reverse phase HPLC of a tryptic hydrolysate of α_2 -casein in a gradient of acetonitrile, said peptide fraction corresponding to peak 1, 2, 3 or 4 collected respectively at 25, 29, 57 or 60 min, wherein:

- the peak 1 contains (a) the peptide TVY (SEQ ID NO: 1);
- the peak 2 contains (b) the peptide NMAINPSK (SEQ ID NO: 2);
- the peak 3 contains (c) the peptide FALPQY (SEQ ID NO: 3);
- the peak 4 contains (d) the peptides peptide FPQYQLQY (SEQ ID NO: 4) and/or (e) the peptide FALPQYQLK (SEQ ID NO: 5).

wherein said pharmaceutical composition has peptides have inhibiting activity on angiotensin converting enzyme (ACE) ACE, with IC₅₀ values equal to or less than 60 μM.

Claim 8. (Currently Amended) A the pharmaceutical composition of claim 1 which comprises containing as its active ingredient an effective quantity of one or more peptide fractions the peptide of SEQ ID NO: 5 according to claim 1, in combination with a pharmaceutically acceptable vehicle.

Claim 9. (Currently Amended) A food product comprising, in combination with a food base, at least two peptides which are

- (a) the peptide TVY (SEQ ID NO: 1);
- (b) the peptide NMAINPSK (SEQ ID NO: 2);
- (c) the peptide FALPQY (SEQ ID NO: 3);
- (d) the peptide FPQYLQY (SEQ ID NO: 4) or
- (e) the peptide FALPQYLN (SEQ ID NO: 5),

wherein said food base comprising said peptides has inhibiting activity on ACE, with IC₅₀ values equal to or less than 60 μM an-effective quantity of one or more peptide fractions according to claim 1, in combination with a food base.

Claim 10. (Currently Amended) A The food product according to claim 9 further comprising at least one peptide which is of the peptide fractions corresponding to peaks 5, 6 and 7 eluted respectively at 52, 59 and 31 min, wherein:

- the peak 5 contains (f) the peptide ALNEINQFYQK (SEQ ID NO: 8);
- the peak 6 contains (g) the peptide ALNEINQFY (SEQ ID NO: 9), or
- the peak 6 contains (h) the peptide YL (SEQ ID NO: 10).

Claim 11. (Currently Amended) A method of preparation of a pharmaceutical composition having antihypertensive activity comprising

fractioning a tryptic hydrolysate of α_{s2} casein by reverse phase high performance liquid chromatography (HPLC) HPLC in a gradient of acetonitrile, obtaining peptide fraction corresponding to peak 1, 2, 3 or 4 collected respectively at 25, 29, 57 or 60 min, wherein:

- peak 1 contains the peptide TVY (SEQ ID NO: 1);
- peak 2 contains the peptide NMAINPSK (SEQ ID NO: 2);
- peak 3 contains the peptide FALPQY (SEQ ID NO: 3);
- peak 4 contains the peptide FPQYLQY (SEQ ID NO: 4) and FALPQYLN (SEQ ID NO: 5);

wherein said peptides have inhibiting activity on angiotensin converting enzyme (ACE) ACE, with IC₅₀ values equal or less than 60 μM,

and

combining an effective amount of at least two peptides of SEQ ID NOs: 1-5 with a pharmaceutically acceptable vehicle using one or more of said peptide fractions to prepare a pharmaceutical composition having antihypertensive activity.

Claim 12. (Currently Amended) A The food product according to claim 9, wherein said food base comprises a protein, lipid, or a carbohydrate.

Claim 13. (Currently Amended) A method of inhibiting angiotensin I converting enzyme (ACE) comprising contacting said enzyme with a peptide fraction the pharmaceutical composition of claim 1.

Claim 14. (Currently Amended) A method of treating hypertension comprising administering to a subject in need thereof an effective amount of a peptide fraction the pharmaceutical composition of claim 1.